Panobinostat (LBH589) in Patients With Metastatic Melanoma

Inclusion Criteria: * Histologically or cytologically confirmed metastatic melanoma * Measurable disease * 18 years of age or older * ECOG performance status of 0, 1 or 2 * Normal organ and marrow function as outlined in the protocol * Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first administration of study treatment and must be willing to use two methods of contraception during the study and for 3 months after last study drug administration * Clinically euthyroid * Biopsiable disease: Disease must be in the opinion of the treating investigator biopsiable such that there are minimal risks involved Exclusion Criteria: * Chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * May not be receiving any other study agents, anti-cancer therapy or radiation therapy * Known brain metastases or any history of brain metastases * History of allergic reactions attributed to compounds of similar chemical or biologic composition to LBH589 * Concomitant use of drugs with a risk of causing torsades de pointes * Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer * Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment * Impaired cardiac function * Uncontrolled hypertension * Patients with unresolved diarrhea grade 2 or greater * Impairment of the gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589 * Pregnant or breastfeeding women * Individuals with a history of a different malignancy are ineligible except for the following circumstances: disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy; individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin. * Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C * Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent * Uncontrolled and/or severe intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements